vs
Ardmore Shipping Corp（ASC）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
VERACYTE, INC.的季度营收约是Ardmore Shipping Corp的1.7倍（$140.6M vs $81.2M），VERACYTE, INC.净利率更高（29.3% vs 15.7%，领先13.5%），VERACYTE, INC.同比增速更快（18.5% vs -15.5%），过去两年VERACYTE, INC.的营收复合增速更高（20.5% vs -6.0%）
阿德莫尔航运是一家全球化海上运输企业，持有并运营中型成品油轮与化学品运输船队，可为全球能源、化工及贸易领域客户提供石油产品、特种化学品及其他散装液态货物的海运服务。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
ASC vs VCYT — 直观对比
营收规模更大
VCYT
是对方的1.7倍
$81.2M
营收增速更快
VCYT
高出34.0%
-15.5%
净利率更高
VCYT
高出13.5%
15.7%
两年增速更快
VCYT
近两年复合增速
-6.0%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $81.2M | $140.6M |
| 净利润 | $12.8M | $41.1M |
| 毛利率 | — | 72.5% |
| 营业利润率 | 16.1% | 26.4% |
| 净利率 | 15.7% | 29.3% |
| 营收同比 | -15.5% | 18.5% |
| 净利润同比 | -47.0% | 704.8% |
| 每股收益（稀释后） | $0.30 | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASCVCYT
| Q4 25 | — | $140.6M | ||
| Q3 25 | $81.2M | $131.9M | ||
| Q2 25 | $72.0M | $130.2M | ||
| Q1 25 | $74.0M | $114.5M | ||
| Q4 24 | — | $118.6M | ||
| Q3 24 | $96.1M | $115.9M | ||
| Q2 24 | $121.3M | $114.4M | ||
| Q1 24 | $106.3M | $96.8M |
净利润ASCVCYT
| Q4 25 | — | $41.1M | ||
| Q3 25 | $12.8M | $19.1M | ||
| Q2 25 | $9.6M | $-980.0K | ||
| Q1 25 | $6.3M | $7.0M | ||
| Q4 24 | — | $5.1M | ||
| Q3 24 | $24.1M | $15.2M | ||
| Q2 24 | $62.7M | $5.7M | ||
| Q1 24 | $39.2M | $-1.9M |
毛利率ASCVCYT
| Q4 25 | — | 72.5% | ||
| Q3 25 | — | 69.2% | ||
| Q2 25 | — | 69.0% | ||
| Q1 25 | — | 69.5% | ||
| Q4 24 | — | 66.4% | ||
| Q3 24 | — | 68.2% | ||
| Q2 24 | — | 68.1% | ||
| Q1 24 | — | 64.5% |
营业利润率ASCVCYT
| Q4 25 | — | 26.4% | ||
| Q3 25 | 16.1% | 17.4% | ||
| Q2 25 | 13.5% | -4.0% | ||
| Q1 25 | 8.6% | 2.5% | ||
| Q4 24 | — | 3.5% | ||
| Q3 24 | 25.4% | 10.4% | ||
| Q2 24 | 51.3% | 4.0% | ||
| Q1 24 | 37.2% | -4.8% |
净利率ASCVCYT
| Q4 25 | — | 29.3% | ||
| Q3 25 | 15.7% | 14.5% | ||
| Q2 25 | 13.3% | -0.8% | ||
| Q1 25 | 8.5% | 6.2% | ||
| Q4 24 | — | 4.3% | ||
| Q3 24 | 25.1% | 13.1% | ||
| Q2 24 | 51.7% | 5.0% | ||
| Q1 24 | 36.9% | -1.9% |
每股收益（稀释后）ASCVCYT
| Q4 25 | — | $0.50 | ||
| Q3 25 | $0.30 | $0.24 | ||
| Q2 25 | $0.22 | $-0.01 | ||
| Q1 25 | $0.14 | $0.09 | ||
| Q4 24 | — | $0.07 | ||
| Q3 24 | $0.55 | $0.19 | ||
| Q2 24 | $1.47 | $0.07 | ||
| Q1 24 | $0.92 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $362.6M |
| 总债务越低越好 | $116.1M | — |
| 股东权益账面价值 | $628.2M | $1.3B |
| 总资产 | $799.8M | $1.4B |
| 负债/权益比越低杠杆越低 | 0.18× | — |
8季度趋势，按日历期对齐
现金及短期投资ASCVCYT
| Q4 25 | — | $362.6M | ||
| Q3 25 | — | $315.6M | ||
| Q2 25 | — | $219.5M | ||
| Q1 25 | — | $186.1M | ||
| Q4 24 | — | $239.1M | ||
| Q3 24 | — | $274.1M | ||
| Q2 24 | — | $235.9M | ||
| Q1 24 | — | $209.2M |
总债务ASCVCYT
| Q4 25 | — | — | ||
| Q3 25 | $116.1M | — | ||
| Q2 25 | $25.0M | — | ||
| Q1 25 | $20.5M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $22.5M | — | ||
| Q2 24 | $44.2M | — | ||
| Q1 24 | $23.1M | — |
股东权益ASCVCYT
| Q4 25 | — | $1.3B | ||
| Q3 25 | $628.2M | $1.3B | ||
| Q2 25 | $618.3M | $1.2B | ||
| Q1 25 | $610.7M | $1.2B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | $627.0M | $1.2B | ||
| Q2 24 | $617.7M | $1.1B | ||
| Q1 24 | $567.9M | $1.1B |
总资产ASCVCYT
| Q4 25 | — | $1.4B | ||
| Q3 25 | $799.8M | $1.4B | ||
| Q2 25 | $703.8M | $1.3B | ||
| Q1 25 | $690.4M | $1.3B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | $722.8M | $1.3B | ||
| Q2 24 | $742.0M | $1.2B | ||
| Q1 24 | $704.1M | $1.2B |
负债/权益比ASCVCYT
| Q4 25 | — | — | ||
| Q3 25 | 0.18× | — | ||
| Q2 25 | 0.04× | — | ||
| Q1 25 | 0.03× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.07× | — | ||
| Q1 24 | 0.04× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $17.9M | $52.6M |
| 自由现金流经营现金流 - 资本支出 | — | $48.8M |
| 自由现金流率自由现金流/营收 | — | 34.7% |
| 资本支出强度资本支出/营收 | — | 2.7% |
| 现金转化率经营现金流/净利润 | 1.40× | 1.28× |
| 过去12个月自由现金流最近4个季度 | — | $126.6M |
8季度趋势，按日历期对齐
经营现金流ASCVCYT
| Q4 25 | — | $52.6M | ||
| Q3 25 | $17.9M | $44.8M | ||
| Q2 25 | $11.2M | $33.6M | ||
| Q1 25 | $26.3M | $5.4M | ||
| Q4 24 | — | $24.5M | ||
| Q3 24 | $39.9M | $30.0M | ||
| Q2 24 | $48.4M | $29.6M | ||
| Q1 24 | $49.2M | $-9.0M |
自由现金流ASCVCYT
| Q4 25 | — | $48.8M | ||
| Q3 25 | — | $42.0M | ||
| Q2 25 | — | $32.3M | ||
| Q1 25 | — | $3.5M | ||
| Q4 24 | — | $20.4M | ||
| Q3 24 | — | $27.7M | ||
| Q2 24 | — | $26.8M | ||
| Q1 24 | — | $-11.1M |
自由现金流率ASCVCYT
| Q4 25 | — | 34.7% | ||
| Q3 25 | — | 31.8% | ||
| Q2 25 | — | 24.8% | ||
| Q1 25 | — | 3.1% | ||
| Q4 24 | — | 17.2% | ||
| Q3 24 | — | 23.9% | ||
| Q2 24 | — | 23.4% | ||
| Q1 24 | — | -11.5% |
资本支出强度ASCVCYT
| Q4 25 | — | 2.7% | ||
| Q3 25 | — | 2.1% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 1.6% | ||
| Q4 24 | — | 3.5% | ||
| Q3 24 | — | 1.9% | ||
| Q2 24 | — | 2.4% | ||
| Q1 24 | — | 2.2% |
现金转化率ASCVCYT
| Q4 25 | — | 1.28× | ||
| Q3 25 | 1.40× | 2.34× | ||
| Q2 25 | 1.17× | — | ||
| Q1 25 | 4.20× | 0.76× | ||
| Q4 24 | — | 4.80× | ||
| Q3 24 | 1.65× | 1.98× | ||
| Q2 24 | 0.77× | 5.16× | ||
| Q1 24 | 1.25× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASC
暂无分部数据
VCYT
| Testing | $135.8M | 97% |
| Products | $3.8M | 3% |
| Biopharmaceutical And Other | $686.0K | 0% |
